Abstract
Background: Although the treatment of cancer has made evident progress, its morbidity and mortality are still high. A tumor marker is a critical indicator for early cancer diagnosis, and timely cancer detection can efficiently help improve the prognosis of patients. Therefore, it is necessary to identify novel markers associated with cancer. LncRNA myocardial infarction associated transcript (MIAT) is a newly identified tumor marker, and in this study, we aimed to explore the relationship between MIAT and clinicopathological features and patient prognosis.Methods: We searched PubMed, Embase, Web of Science, and The Cochrane Library from inception to September 2020 to identify correlational studies. Then, we extracted valid data and used Stata software to make forest plots. We used the hazard ratio (HR) or odds ratio (OR) with 95% CI to evaluate the relationship between aberrant expression of MIAT and patients' prognosis and clinicopathological features.Results: The study included 21 studies, containing 2,048 patients. Meta-analysis showed that overexpression of lncRNA MIAT was associated with poor overall survival (OS) (HR = 1.60, 95% CI, 1.31–1.96, p < 0.001). In addition, high expression of MIAT could forecast tumor size (OR = 2.26, 95% CI 1.34–3.81, p = 0.002), distant metastasis (OR = 2.54, 95% CI 1.84–3.50, p < 0.001), TNM stage (OR = 2.38, 95% CI 1.36–4.18, p = 0.002), lymph node metastasis (OR = 2.59, 95% CI 1.25–5.36, p = 0.011), and the degree of differentiation (OR = 2.65, 95% CI 1.54–4.58, p < 0.001). However, other clinicopathological features, including age (OR = 1.07, 95% CI 0.87–1.32, p = 0.516), gender (OR = 0.95, 95% CI 0.77–1.19, p = 0.668), and histology (OR = 0.72, 95% CI 0.48–1.10, p = 0.128) were not significantly different from high expression of MIAT.Conclusions: Our study showed that overexpression of MIAT is related to poor overall survival and clinicopathological features. MIAT can be considered a novel tumor marker to help diagnose tumors earlier and improve patient prognosis.
Highlights
With high incidence and mortality rates, cancer has been a threat to global human health (Wu et al, 2016)
The inclusion criteria were as follows: (1) Long non-coding RNA (lncRNA) myocardial infarction associated transcript (MIAT) expression in cancer tissues; (2) patients were divided into two groups based on lncRNA MIAT expression levels; (3) the study provided at least one of the following clinical outcomes: overall survival (OS), poor lncRNA MIAT in Cancer Prognosis histological grade, earlier distant metastasis, high tumor stage and lymph node metastasis, and the number of patients with larger tumor size; (4) sufficient data were extracted to compute the hazard ratio (HR) and 95% CI of survival or the odds ratio (OR) and 95% CI of clinicopathological parameters
Based on the p-value, we discovered that MIAT, MIAT_EXON5_1, and SBK1 ranked as the top three different predicted target genes, which showed that they were related to lncRNA MIAT gene expression
Summary
With high incidence and mortality rates, cancer has been a threat to global human health (Wu et al, 2016). It is critical to identify novel tumor markers for diagnosis, prognosis, and tumor treatment. LncRNA can be viewed as potential tumorigenic and antitumorigenic RNA (Huarte and Rinn, 2010). Due to their specific expression and functional diversity in various cancer types, lncRNA has promising cancer diagnosis applications, prognosis, and therapeutic effects. A tumor marker is a critical indicator for early cancer diagnosis, and timely cancer detection can efficiently help improve the prognosis of patients. It is necessary to identify novel markers associated with cancer. LncRNA myocardial infarction associated transcript (MIAT) is a newly identified tumor marker, and in this study, we aimed to explore the relationship between MIAT and clinicopathological features and patient prognosis
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
